BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 184 filers reported holding BRIDGEBIO PHARMA INC in Q3 2022. The put-call ratio across all filers is 0.89 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,969,310 | +46.6% | 378,055 | -4.3% | 0.03% | +52.9% |
| Q2 2023 | $6,798,214 | +28.5% | 395,245 | +23.8% | 0.02% | +21.4% |
| Q1 2023 | $5,291,258 | +187.6% | 319,135 | +32.2% | 0.01% | +180.0% |
| Q4 2022 | $1,839,735 | -25.0% | 241,435 | -2.1% | 0.01% | -28.6% |
| Q3 2022 | $2,452,000 | +553.9% | 246,700 | +497.6% | 0.01% | +600.0% |
| Q2 2022 | $375,000 | +34.4% | 41,280 | +50.2% | 0.00% | 0.0% |
| Q1 2022 | $279,000 | -69.0% | 27,480 | -49.0% | 0.00% | -50.0% |
| Q4 2021 | $900,000 | -87.1% | 53,935 | -63.9% | 0.00% | -88.9% |
| Q3 2021 | $6,995,000 | -55.4% | 149,250 | -42.0% | 0.02% | -56.1% |
| Q2 2021 | $15,682,000 | -43.0% | 257,250 | -42.4% | 0.04% | -46.1% |
| Q1 2021 | $27,501,000 | +207.2% | 446,450 | +254.6% | 0.08% | +216.7% |
| Q4 2020 | $8,953,000 | – | 125,900 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 3,835,722 | $103,449,000 | 44.18% |
| Kohlberg Kravis Roberts & Co. L.P. | 36,900,661 | $995,211,000 | 12.26% |
| SC US (TTGP), LTD. | 2,544,738 | $68,632,000 | 4.69% |
| Cormorant Asset Management, LP | 2,780,885 | $75,000,000 | 4.31% |
| Perceptive Advisors | 6,706,268 | $180,868,000 | 4.15% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $717,968,000 | 3.22% |
| Hillhouse Capital Management | 2,035,790 | $54,905,000 | 1.75% |
| Alpine Group USVI, LLC | 20,000 | $539,000 | 1.70% |
| HHLR ADVISORS, LTD. | 2,352,900 | $63,458,000 | 1.42% |
| SCGE MANAGEMENT, L.P. | 588,235 | $15,865,000 | 0.79% |